<DOC>
	<DOCNO>NCT01643408</DOCNO>
	<brief_summary>This study utilize Erwinaze via intravenous administration patient age 1 30 experienced allergy frontline therapy . The study determine proportion patient 2 day nadir serum asparaginase activity level &gt; 0.1 IU/mL first 2 week treatment 3 time per week IV dosing .</brief_summary>
	<brief_title>A Study Erwinaze Administered Intravenously Patients Who Had Allergy Frontline Asparaginase Therapy</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>Diagnosis Acute Lymphoblastic Leukemia ( ALL ) Lymphoblastic Lymphoma , Ages &gt; /= 1 &lt; /= 30 year time initial diagnosis Undergoing asparaginase treatment ALL lymphoblastic lymphoma Documented Grade 2 high hypersensitivity reaction native pegylated E. coli asparaginase Calaspargase pegol Must two remain week native E. coli asparaginase treatment 1 remain dose either Pegaspargase Calaspargase pegol Direct bilirubin less equal Grade 2 Amylase lipase within normal limit ( per institutional standard ) sign informed consent byt patient great equal 18 year parent patient young 18 year old .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Lymphoblastic Lymphoma</keyword>
	<keyword>Erwinaze</keyword>
	<keyword>asparaginase</keyword>
	<keyword>Eusa Pharma</keyword>
	<keyword>Pharmacokinetic study</keyword>
	<keyword>NSAA</keyword>
</DOC>